Table 1. Half maximal effective concentration (EC50) of raloxifene against Leishmania spp.
Leishmania species | Stagea | Condition (medium or buffer) | Time of incubation (hours) | EC50 ± SDb |
L. amazonensis | P | M199 | 24 | 30.2±1.7 |
L. amazonensis | P | M199 | 2 | 30.6±1.0 |
L. amazonensis | P | HBSS+Glc | 2 | 9.3±1.0 |
L. braziliensis | P | M199 | 24 | 38.0±8.4 |
L. donovani | P | M199 | 24 | 32.5±1.3 |
L. infantum chagasi | P | M199 | 24 | 30.9±0.5 |
L. major | P | M199 | 24 | 32.6±1.4 |
L. mexicana | P | M199 | 24 | 30.3±1.3 |
L. amazonensis | LA | RPMI | 24 | 15.0±2.3 |
L. amazonensis | IA | RPMI | 48 | 16.2±2.2 |
L. infantum chagasi | IA | RPMI | 48 | 8.8±1.1 |
Parasite form: P: promastigotes; LA: lesion derived amastigotes; IA: intracelullar amastigotes. Half maximal effective concentration against promastigotes and axenic lesion-derived amastigotes was determined through MTT or MTS as described [20]; activity against L. amazonensis and L. infantum chagasi intracellular amastigotes was determined through luciferase activity or microscopic counting, respectively, as described in Material and Methods.
The results are expressed as the mean and standard deviation (± SD) of three independent experiments, each one performed in triplicate.